Research and Markets (http://www.researchandmarkets.com/research/111f63/tnm_classification) has announced the addition of John Wiley and Sons Ltd's new report "TNM Classification of Malignant Tumours, 7th Edition" to their offering.
“TNM Classification of Malignant Tumours, 7th Edition”
TNM Classification of Malignant Tumours, 7th Edition offers a truly international approach to cancer classification and staging, with the latest information and best evidence carefully vetted and included by a multidisciplinary panel of experts from around the world. The material is therefore immediately applicable to patients worldwide, and not influenced by any particular healthcare system.
The book's greatest virtue continues to be its simplicity, distilling and arranging complex data in a way that is immediately applicable wherever cancer patients are seen.
TNM Classification of Malignant Tumours, 7th Edition provides the latest, internationally agreed-upon standards to describe and categorize cancer stages and progression. Published in affiliation with the International Union Against Cancer (UICC), this authoritative guide contains important updated organ-specific classifications that oncologists and other professionals who manage patients with cancer need to accurately classify tumours for staging, prognosis and treatment.
The major alterations addressed in the 7th Edition concern carcinomas of the oesophagus and the gastroesophageal junction, stomach, lung, appendix, biliary tract, skin, and prostate. In addition, there are several entirely new classifications:
- gastrointestinal carcinoids (neuroendocrine tumours)
- gastrointestinal stromal tumour
- upper aerodigestive mucosal melanoma
- Merkel cell carcinoma
- uterine sarcomas
- intrahepatic cholangiocarcinoma
- adrenal cortical carcinoma.
A new approach has also been adopted to separate anatomical stage groupings from prognostic groupings in which other prognostic factors are added to T, N, and M categories. These new prognostic groupings, as well as the traditional anatomical groupings, are presented for oesophageal and prostate carcinomas.